Citius Oncology (NASDAQ:CTOR) Coverage Initiated by Analysts at Maxim Group

Stock analysts at Maxim Group initiated coverage on shares of Citius Oncology (NASDAQ:CTOR) in a research report issued on Wednesday, MarketBeat Ratings reports. The brokerage set a “buy” rating and a $3.00 price target on the stock. Maxim Group’s price objective would indicate a potential upside of 219.08% from the stock’s previous close.

Citius Oncology Price Performance

Citius Oncology stock opened at $0.94 on Wednesday. Citius Oncology has a 12 month low of $0.85 and a 12 month high of $49.00. The stock has a fifty day simple moving average of $1.18.

Citius Oncology Company Profile

TenX Keane Acquisition Corp. is a blank check company. It formed for the purpose to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses. TenX Keane Acquisition Corp. is based in New York.